neuropsychiatric disease. Operations thus focus on selecting product candidates to license-in, adding value by advancing towards global registration, and licensing-out to commercial partners. There success reflects an exceptional ability to select promising drug candidates, intimate knowledge of the development process as well as our ability to devise the most efficient path to regulatory approval.

Since inception, CPC has sought to develop novel compounds that could improve the treatment of AD and related neurodegenerative disorders. Alzheimer’s disease constitutes the largest unmet medical need in neuropsychiatry. No emerging therapies have clearly demonstrated the potential to fulfill this medical need. Symptoms include an increasing loss of memory and other cognitive functions later combined with a variety of neuropsychiatric and behavioral disturbances. Progression is relentless, typically leading to death within 10 to 15 years. AD is now recognized as the third leading killer in the U.S. It is estimated that the 37 million afflicted worldwide cost society over $600 billion annually. As the population ages, this burden will rapidly climb to unsustainable levels. Although US sales of Alzheimer’s disease medications last year topped $4.7 billion, none of the current treatments improve symptoms more than marginally. Moreover, tolerability is poor, dose titration prolonged, and dropout rates high.

Chase founders have invented and patented a unique combination of proven, currently marketed pharmaceuticals that we believe will benefit the symptomatic treatment of AD.